Zacks.com featured highlights include Globus Medical, NetApp and Assurant

Zacks highlighted Globus Medical, NetApp and Assurant as sales-growth picks despite market headwinds from Middle East tensions, higher oil prices, inflation, tariffs and elevated Treasury yields. Expected 2026 sales growth is 8.8% for Globus Medical and 8.5% for Assurant, while NetApp is projected to grow revenue 18.6% in fiscal 2027. GMED holds a Zacks Rank #1, while NTAP and AIZ hold Rank #2 ratings; the recommendations are analyst commentary rather than a material company-specific catalyst.

Analysis

This is a low-information quantitative screen rather than a company-specific catalyst, so any near-term price response should be modest and likely mean-revert absent upward estimate revisions. The key question is not top-line growth alone but incremental gross margin and free-cash-flow conversion; revenue sourced through lower-margin hardware, acquisition accounting, or insurance pass-throughs will not support multiple expansion. Treat the publication as a sentiment datapoint, not independent validation of fundamentals.

NTAP has the clearest potential 1-3 month catalyst path if enterprise AI and hybrid-cloud deployments translate into higher all-flash/data-services mix rather than simply storage capacity growth. That would be most adverse for Dell Technologies (DELL) and Pure Storage (PSTG) only if NetApp demonstrates share gains in cloud-integrated deployments; otherwise, broad AI-storage optimism is more likely to lift the peer group together. Falsification is bookings growth failing to convert to product revenue and deferred revenue, or management maintaining growth while lowering gross-margin or operating-margin expectations.

GMED's earnings sensitivity is more operational: procedure volumes and sales-force productivity determine whether revenue growth produces operating leverage. A sustained hospital-capital-equipment slowdown or weaker elective spine volumes would pressure the thesis faster than a generalized risk-off move, while successful cross-selling and share capture could create a 6-18 month margin upside not captured by a simple sales screen. AIZ is the more defensive name, but its quality of growth depends on partner-program economics and loss experience; device replacement inflation or adverse contract repricing can absorb revenue gains before they reach EPS.

Contrarian view: the screen may encourage investors to overpay for visible revenue growth while overlooking that elevated rates reward durable cash generation and estimate durability. Among the three, NTAP offers the largest upside if AI-related demand drives a mix upgrade, but also the highest narrative-risk exposure; GMED may provide the better risk-adjusted idiosyncratic setup if execution metrics improve without requiring an AI multiple.

Key Decisions for Investors

• No immediate directional trade solely on the Zacks ranking; wait for the next earnings cycle and initiate positions only after consensus FY revenue and EPS estimates rise together. Revenue-only estimate increases without margin support are a pass.
• Watch-list long NTAP versus short PSTG in equal dollar size over a 1-3 month horizon only if NTAP reports accelerating all-flash/cloud-data-services growth and raises operating-margin outlook. Target 8-12% relative upside; exit if NTAP's guidance implies growth is hardware-led or if PSTG shows superior subscription/recurring-revenue acceleration.
• Accumulate GMED on post-earnings weakness if procedure-volume commentary and sales-force productivity support operating leverage; frame as a 6-12 month position with a 15% upside objective. Reduce or exit on a material cut to procedure-growth assumptions, hospital capital-spending deterioration, or evidence that revenue growth is requiring disproportionate selling expense.
• Use AIZ as the defensive expression only after confirming that partner-program revenue growth is accompanied by stable or improving adjusted EBITDA margin and loss ratios. A 6-18 month long is appropriate against a cyclical consumer-finance short basket; invalidate if device-claim severity, housing-related losses, or partner concentration causes a guidance reduction.